In cases of adjuvant-induced arthritis, administration of AUR and UMB concurrently with the induction of arthritis showed the ability to reduce serum IL-17 levels, while UMB treatment alone exhibited the capacity to suppress local inflammation [32]. The gene discussed is IL17A; the disease is arthritic joint disease.